{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:44:26Z","timestamp":1782920666008,"version":"3.54.5"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41375-026-02999-y","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T11:57:18Z","timestamp":1780919838000},"page":"1547-1550","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comprehensive landscape of secondary cytogenetic and molecular genetic events in multiple myeloma patients at diagnosis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4049-1217","authenticated-orcid":false,"given":"Jana","family":"Wobst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marietta","family":"Truger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Wossidlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2432-8898","authenticated-orcid":false,"given":"Stephan","family":"Hutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-3265","authenticated-orcid":false,"given":"Manja","family":"Meggendorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6452-2874","authenticated-orcid":false,"given":"Wolfgang","family":"Kern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0196-2837","authenticated-orcid":false,"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6333-5049","authenticated-orcid":false,"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2999_CR1","first-page":"e528","volume":"5","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, et al. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. Hemasphere. 2021;5:e528.","journal-title":"Hemasphere"},{"key":"2999_CR2","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046\u201360.","journal-title":"N Engl J Med"},{"key":"2999_CR3","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"2999_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2024.101168","volume":"64","author":"SE Clarke","year":"2024","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","journal-title":"Blood Rev"},{"key":"2999_CR5","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cpt.2023.12.004","volume":"2","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang M, Chu B, Lu M, Shi L, Gao S, et al. Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology. Cancer Pathog Ther. 2024;2:205\u201311.","journal-title":"Cancer Pathog Ther"},{"key":"2999_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0191-y","volume":"9","author":"A Lakshman","year":"2019","unstructured":"Lakshman A, Painuly U, Rajkumar SV, Ketterling RP, Kapoor P, Greipp PT, et al. Natural history of multiple myeloma with de novo del(17p). Blood Cancer J. 2019;9:32.","journal-title":"Blood Cancer J"},{"key":"2999_CR7","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"2999_CR8","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.3324\/haematol.2012.081083","volume":"98","author":"S Van Wier","year":"2013","unstructured":"Van Wier S, Braggio E, Baker A, Ahmann G, Levy J, Carpten JD, et al. Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma. Haematologica. 2013;98:1586\u201392.","journal-title":"Haematologica"},{"key":"2999_CR9","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/leu.2016.253","volume":"31","author":"JR Sawyer","year":"2017","unstructured":"Sawyer JR, Tian E, Shaughnessy JD Jr, Epstein J, Swanson CM, Stangeby C, et al. Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma. Leukemia. 2017;31:637\u201344.","journal-title":"Leukemia"},{"key":"2999_CR10","doi-asserted-by":"publisher","first-page":"3420","DOI":"10.1080\/10428194.2021.1964021","volume":"62","author":"S Bendig","year":"2021","unstructured":"Bendig S, Walter W, Meggendorfer M, B\u00e4r C, Fuhrmann I, Kern W, et al. Whole genome sequencing demonstrates substantial pathophysiological differences of MYC rearrangements in patients with plasma cell myeloma and B-cell lymphoma. Leuk Lymphoma. 2021;62:3420\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2999_CR11","doi-asserted-by":"publisher","first-page":"5814","DOI":"10.1182\/bloodadvances.2025017214","volume":"9","author":"A Spencer","year":"2025","unstructured":"Spencer A, Gavriatopoulou M, Coriu D, Lysen A, Gutierrez NC, Escalante F, et al. Prospective real-world evaluation of t(11;14) prevalence and disease biology in multiple myeloma: MEDICI study analysis. Blood Adv. 2025;9:5814\u201327.","journal-title":"Blood Adv"},{"key":"2999_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI180065","volume":"134","author":"WG Dunn","year":"2024","unstructured":"Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134:e180065.","journal-title":"J Clin Invest"},{"key":"2999_CR13","doi-asserted-by":"crossref","unstructured":"Wobst J, Wossidlo N, Truger M, Meggendorfer M, Kern W, Haferlach T, et al. Clonal independence of CHIP-associated mutations in multiple myeloma. Leuk Lymphoma 2026;1-4.","DOI":"10.1080\/10428194.2026.2617435"},{"key":"2999_CR14","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3324\/haematol.2021.278342","volume":"107","author":"K Todoerti","year":"2022","unstructured":"Todoerti K, Ronchetti D, Favasuli V, Maura F, Morabito F, Bolli N, et al. DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome. Haematologica. 2022;107:921\u201332.","journal-title":"Haematologica"},{"key":"2999_CR15","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.2022017863","volume":"141","author":"A Schavgoulidze","year":"2023","unstructured":"Schavgoulidze A, Talbot A, Perrot A, Cazaubiel T, Leleu X, Manier S, et al. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor. Blood. 2023;141:1308\u201315.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02999-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02999-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02999-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T14:49:12Z","timestamp":1782917352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-02999-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2999"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-02999-y","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"6 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"WK, TH and CH declare part ownership of MLL Munich Leukemia Laboratory. JW, MT, NW, SH and MM are employed by MLL Munich Leukemia Laboratory.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All patients gave their informed consent for genetic analyses and the use of laboratory results for research purposes. The study adhered to the tenets of the Declaration of Helsinki and was approved by the laboratory\u00b4s institutional review board and the Ethics Committee of the Bavarian Medical Association for the use of archived DNA\/RNA samples and associated clinical information. The clinical data were retrieved and the samples were collected and analyzed with the endorsement of the Ethics Committee of the Bavarian Medical Association.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}